Brings more than three decades of leadership experience in the life sciences industry RADNOR, Pa., Oct. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Gregory T. Lucier to its Board of Directors. Mr. Lucier brings significant experience and broad expertise across the healthcare landscape to the Avantor Board. He founded

TEL AVIV, Israel, Oct. 3, 2025 /PRNewswire/ -- MedHub-AI today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved national reimbursement for the company's AutocathFFR™ System, effective October 1, 2025. The decision follows regulatory approval by the Pharmaceuticals and Medical Devices Agency (PMDA) earlier this year and marks a significant milestone in expanding access to advanced coronary physiology assessment in Japan. The approval provides physicians and h

A roundup of the most newsworthy healthcare press releases from PR Newswire, including new funding for the development of medical treatments, expansion in pharmaceuticals manufacturing and mental health awareness initiatives. NEW YORK, Oct. 3, 2025 /PRNewswire/ -- With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most popular releases and newsworthy trends

Ovid Therapeutics saw its stock jump Friday morning after it announced it would advance an epilepsy drug and revealed a new PIPE financing. Ovid shares $OVID rose 19% at market open on Phase 1 data showing a program called OV329, a GABA-AT inhibitor, was safe in healthy volunteers and performed well in biomarker analyses. In the study, 51 participants received OV329 and only three treatment-related side effects emerged, all of which were mild: headache, drowsiness and metallic taste. Meanwhile,

HEIDELBERG, Germany, Oct. 3, 2025 /PRNewswire/ -- Mediso completes the installation of an AnyScan® TRIO-TheraMAX SPECT/CT at the Department of Nuclear Medicine at Heidelberg University Hospital. Continue Reading AnyScan® TRIO-TheraMAX SPECT/CT installed at Heidelberg University Hospital (PRNewsfoto/Mediso) The system is specifically designed for the clinical needs of theranostic imaging. Its detectors and collimators are developed for Targeted Radionuclide Therapies carried out with radioisotop

Cidara Therapeutics has secured an award from HHS valued at up to $339 million for onshore manufacturing and additional clinical research for its investigational antiviral biologic designed to prevent seasonal and pandemic flu infections. The award from the US’ Biomedical Advanced Research and Development Authority (BARDA) will have an initial funding of $58 million over the next two years so that Cidara can move manufacturing of CD388 to the US. The funds will also be used to support future cli

ROME and MILAN, Oct. 3, 2025 /PRNewswire/ -- The Department of Clinical and Molecular Medicine of Sapienza University of Rome (DMCM), Takis S.r.l. and Tethis S.p.A. today announce a joint initiative, to accelerate research on HER3-targeted therapies and advance the development of companion diagnostics for lung cancer patients. Continue Reading Takis Logo Sapienza University of Rome (DMCM) Logo Within the framework of the HERCART project, funded by the Italian Ministry of Enterprises and Made i

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC*3 Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has a

Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for t

Ovid Therapeutics' stock climbed about 13% in premarket trade Friday after the biotech reported early data for its epilepsy drug candidate OV329. According to Ovid, results showed the oral therapy penetrated the brain and produced significant inhibitory effects on neuronal activity at levels comparable to or exceeding those of an older drug, while avoiding the vision-related side effects that have hampered use of existing treatments.OV329 is a next-generation inhibitor of the GABA-aminotransfera